Latest Pharma Insights
J&J Joins Trump Administration’s MFN Pricing Initiative
The announced deal means that of 17 companies the White House notified in July, only AbbVie and Regeneron have not yet made a deal.
Scrip - January 9, 2026
The announced deal means that of 17 companies the White House notified in July, only AbbVie and Regeneron have not yet made a deal.
Scrip - January 9, 2026
Medtech 2026: As Critical New Documents Drop, EU Leaders Look Ahead
The EU's medtech regulatory landscape is shifting, influenced by the Commission's proposed changes. Experts note opportunities and concerns emerging from these reforms, highlighting the need for transparency, efficiency, and adaptability to new technologies by 2026.
Medtech Insight - January 9, 2026
The EU's medtech regulatory landscape is shifting, influenced by the Commission's proposed changes. Experts note opportunities and concerns emerging from these reforms, highlighting the need for transparency, efficiency, and adaptability to new technologies by 2026.
Medtech Insight - January 9, 2026
Global Medtech Guidance Tracker: December 2025
Stay current on regulatory guidelines from around the world with Medtech Insight’s Guidance Tracker. Over 70 documents have been posted on the tracker since its last update.
Medtech Insight - January 9, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight’s Guidance Tracker. Over 70 documents have been posted on the tracker since its last update.
Medtech Insight - January 9, 2026
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m
Public Company Edition: Aktis’s public market debut sets a positive IPO tone for 2026. Also, follow-on offerings grossed $825m for Arrowhead, $575m for Praxis, $350m for Crinetics and $300m each for Alumis and Monte Rosa ahead of the J.P. Morgan Healthcare Conference.
Scrip - January 9, 2026
Public Company Edition: Aktis’s public market debut sets a positive IPO tone for 2026. Also, follow-on offerings grossed $825m for Arrowhead, $575m for Praxis, $350m for Crinetics and $300m each for Alumis and Monte Rosa ahead of the J.P. Morgan Healthcare Conference.
Scrip - January 9, 2026
Asian Offerings Again Outpace Western Biopharma IPOs In Q4
Drug developers executed just two initial public offerings in the US during the fourth quarter of 2025 versus six IPOs in China and South Korea, continuing a year-long trend.
Scrip - January 9, 2026
Drug developers executed just two initial public offerings in the US during the fourth quarter of 2025 versus six IPOs in China and South Korea, continuing a year-long trend.
Scrip - January 9, 2026
Scrip Asks... What Does 2026 Hold For Biopharma? Part 1: Capital Allocation And Dealmaking
Industry leaders, executives and investors forecast that M&A will accelerate in 2026, driven by patent cliff urgency. However, capital is becoming more selective, flowing towards proven assets, novel biology and innovative financing structures.
Scrip - January 9, 2026
Industry leaders, executives and investors forecast that M&A will accelerate in 2026, driven by patent cliff urgency. However, capital is becoming more selective, flowing towards proven assets, novel biology and innovative financing structures.
Scrip - January 9, 2026
Five Clinical Trials That Missed The Mark (Or Barely Hit It) In 2025
Some negative or mixed studies had significant negative effects on their sponsors, while others rolled off their backs. Scrip takes a look at five trials that missed the mark or hit it, but not enough to yield positive results.
Scrip - January 9, 2026
Some negative or mixed studies had significant negative effects on their sponsors, while others rolled off their backs. Scrip takes a look at five trials that missed the mark or hit it, but not enough to yield positive results.
Scrip - January 9, 2026
US House Bill On Green Packaging Claims Takes Aim At State-Level Regulations
A new bill introduced in the US House of Representatives seeks to curb the patchwork of packaging regulations for consumer products in different states with a federal standard.
HBW Insight - January 9, 2026
A new bill introduced in the US House of Representatives seeks to curb the patchwork of packaging regulations for consumer products in different states with a federal standard.
HBW Insight - January 9, 2026
India’s Medtech Momentum Brings 10-12% Market Growth But Concerns About Stalling Progress in 2026
India’s medical devices industry entered 2026 on the back of steady market growth amid industry warnings over policy inconsistency and ongoing import dependence.
Medtech Insight - January 9, 2026
India’s medical devices industry entered 2026 on the back of steady market growth amid industry warnings over policy inconsistency and ongoing import dependence.
Medtech Insight - January 9, 2026
People On The Move: Appointments at Karo, Haleon, Pharma Deutschland
Round up of latest European people moves: Karo makes additions to corporate team; Haleon names Portugal head; Pharma Deutschland adds experience.
HBW Insight - January 9, 2026
Round up of latest European people moves: Karo makes additions to corporate team; Haleon names Portugal head; Pharma Deutschland adds experience.
HBW Insight - January 9, 2026
Zepbound And Taltz Combo Bolsters Lilly’s Co-Morbidity Plans
Another Phase III hit for Lilly’s Zepbound, the TOGETHER-PsA trial is the first to add an incretin therapy to anti-inflammatory biologic, potentially expanding its reach into another major comorbidity market.
Scrip - January 9, 2026
Another Phase III hit for Lilly’s Zepbound, the TOGETHER-PsA trial is the first to add an incretin therapy to anti-inflammatory biologic, potentially expanding its reach into another major comorbidity market.
Scrip - January 9, 2026
Tranquility Restored For MoonLake With Positive FDA Feedback On HS Drug
The Swiss biotech’s shares jumped by 27% after the US agency said another trial was not needed to submit sonelokimab.
Scrip - January 9, 2026
The Swiss biotech’s shares jumped by 27% after the US agency said another trial was not needed to submit sonelokimab.
Scrip - January 9, 2026
Biocon Biologics Adds Keytruda, Herceptin, Opdivo Biosimilars To Its Portfolio
Biocon Biologics continues to build on its oncology portfolio with three new biosimilar candidates, as the integration into a wholly owned subsidiary of Biocon Limited comes closer.
Generics Bulletin - January 9, 2026
Biocon Biologics continues to build on its oncology portfolio with three new biosimilar candidates, as the integration into a wholly owned subsidiary of Biocon Limited comes closer.
Generics Bulletin - January 9, 2026
Hyloris Taps Rosemont To Commercialize Titratable Atomoxetine Oral Solution In US
Latest agreement with Rosemont underscores Hyloris’ value-added medicines strategy and asset-light US partnering.
Generics Bulletin - January 9, 2026
Latest agreement with Rosemont underscores Hyloris’ value-added medicines strategy and asset-light US partnering.
Generics Bulletin - January 9, 2026
Cosette And Alembic Are Among Latest To Benefit From CGT Pathway
Cosette Pharmaceuticals and Alembic Pharmaceuticals are among the latest firms to have benefited from 180 days of competitive generic therapy exclusivity under the US FDA’s CGT pathway. Since the first approval in 2018, almost 500 ANDAs referencing CGT products have been approved.
Generics Bulletin - January 9, 2026
Cosette Pharmaceuticals and Alembic Pharmaceuticals are among the latest firms to have benefited from 180 days of competitive generic therapy exclusivity under the US FDA’s CGT pathway. Since the first approval in 2018, almost 500 ANDAs referencing CGT products have been approved.
Generics Bulletin - January 9, 2026
BSI’s Tunbridge: Notified Bodies ‘Set Up To Fail’ Unless EU Legislative Proposal Changes
Proposal Gives Unrealistic Timelines And Reflects Poor Grasp Of Notified Body Realities
Medtech Insight - January 9, 2026
Proposal Gives Unrealistic Timelines And Reflects Poor Grasp Of Notified Body Realities
Medtech Insight - January 9, 2026
How Do Aurobindo’s Khandelwal Acquisition, Amicus Settlement, China JV Move Add Up?
What is the strategic intent behind Aurobindo’s moves to settle a Galafold patent dispute with Amicus Therapeutics, acquire the non-oncology business of compatriot Khandelwal Labs and get full control of a Chinese JV with Shandong Luoxin?
Scrip - January 9, 2026
What is the strategic intent behind Aurobindo’s moves to settle a Galafold patent dispute with Amicus Therapeutics, acquire the non-oncology business of compatriot Khandelwal Labs and get full control of a Chinese JV with Shandong Luoxin?
Scrip - January 9, 2026
Roche Doubles Down On SCLC By In-Licensing MediLink’s ADC
Deal Snapshot: Roche has scooped up a B7H3 ADC from China’s MediLink just a few months after Daiichi Sankyo temporarily halted enrolling patients in a pivotal Phase III trial with its same-class rival, Merck-partnered ifinatamab deruxtecan (I-DXd).
Scrip - January 9, 2026
Deal Snapshot: Roche has scooped up a B7H3 ADC from China’s MediLink just a few months after Daiichi Sankyo temporarily halted enrolling patients in a pivotal Phase III trial with its same-class rival, Merck-partnered ifinatamab deruxtecan (I-DXd).
Scrip - January 9, 2026
Hisamitsu To Go Private For Long-Term Growth Through $2.6bn MBO
Hisamitsu's CEO is taking the Japanese firm private through a management buyout aimed at securing future growth.
Scrip - January 9, 2026
Hisamitsu's CEO is taking the Japanese firm private through a management buyout aimed at securing future growth.
Scrip - January 9, 2026
CES Beauty Tech Honorees Offer Window Into Future Skin, Hair Innovations
The Consumer Technology Association’s CES show in Las Vegas Jan. 6-9 showcased breakthrough skin and hair care technologies.
HBW Insight - January 9, 2026
The Consumer Technology Association’s CES show in Las Vegas Jan. 6-9 showcased breakthrough skin and hair care technologies.
HBW Insight - January 9, 2026
Inno Medicine Moves Novel Liposome Into Pivotal Trial For Coronary Plaque
The CEO of Inno Medicine tells Scrip the Chinese company has developed a novel active-targeting nano-liposomal formulation to reverse coronary atherosclerosis plaque, which has yielded positive proof-of-concept Phase Ib/IIa results.
Scrip - January 9, 2026
The CEO of Inno Medicine tells Scrip the Chinese company has developed a novel active-targeting nano-liposomal formulation to reverse coronary atherosclerosis plaque, which has yielded positive proof-of-concept Phase Ib/IIa results.
Scrip - January 9, 2026
J&J Joins Trump Administration’s MFN Pricing Initiative
The announced deal means that of 17 companies the White House notified in July, only AbbVie and Regeneron have not yet made a deal.
Scrip - January 9, 2026
The announced deal means that of 17 companies the White House notified in July, only AbbVie and Regeneron have not yet made a deal.
Scrip - January 9, 2026
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m
Public Company Edition: Aktis’s public market debut sets a positive IPO tone for 2026. Also, follow-on offerings grossed $825m for Arrowhead, $575m for Praxis, $350m for Crinetics and $300m each for Alumis and Monte Rosa ahead of the J.P. Morgan Healthcare Conference.
Scrip - January 9, 2026
Public Company Edition: Aktis’s public market debut sets a positive IPO tone for 2026. Also, follow-on offerings grossed $825m for Arrowhead, $575m for Praxis, $350m for Crinetics and $300m each for Alumis and Monte Rosa ahead of the J.P. Morgan Healthcare Conference.
Scrip - January 9, 2026
Asian Offerings Again Outpace Western Biopharma IPOs In Q4
Drug developers executed just two initial public offerings in the US during the fourth quarter of 2025 versus six IPOs in China and South Korea, continuing a year-long trend.
Scrip - January 9, 2026
Drug developers executed just two initial public offerings in the US during the fourth quarter of 2025 versus six IPOs in China and South Korea, continuing a year-long trend.
Scrip - January 9, 2026
Scrip Asks... What Does 2026 Hold For Biopharma? Part 1: Capital Allocation And Dealmaking
Industry leaders, executives and investors forecast that M&A will accelerate in 2026, driven by patent cliff urgency. However, capital is becoming more selective, flowing towards proven assets, novel biology and innovative financing structures.
Scrip - January 9, 2026
Industry leaders, executives and investors forecast that M&A will accelerate in 2026, driven by patent cliff urgency. However, capital is becoming more selective, flowing towards proven assets, novel biology and innovative financing structures.
Scrip - January 9, 2026
Five Clinical Trials That Missed The Mark (Or Barely Hit It) In 2025
Some negative or mixed studies had significant negative effects on their sponsors, while others rolled off their backs. Scrip takes a look at five trials that missed the mark or hit it, but not enough to yield positive results.
Scrip - January 9, 2026
Some negative or mixed studies had significant negative effects on their sponsors, while others rolled off their backs. Scrip takes a look at five trials that missed the mark or hit it, but not enough to yield positive results.
Scrip - January 9, 2026
Zepbound And Taltz Combo Bolsters Lilly’s Co-Morbidity Plans
Another Phase III hit for Lilly’s Zepbound, the TOGETHER-PsA trial is the first to add an incretin therapy to anti-inflammatory biologic, potentially expanding its reach into another major comorbidity market.
Scrip - January 9, 2026
Another Phase III hit for Lilly’s Zepbound, the TOGETHER-PsA trial is the first to add an incretin therapy to anti-inflammatory biologic, potentially expanding its reach into another major comorbidity market.
Scrip - January 9, 2026
Tranquility Restored For MoonLake With Positive FDA Feedback On HS Drug
The Swiss biotech’s shares jumped by 27% after the US agency said another trial was not needed to submit sonelokimab.
Scrip - January 9, 2026
The Swiss biotech’s shares jumped by 27% after the US agency said another trial was not needed to submit sonelokimab.
Scrip - January 9, 2026
How Do Aurobindo’s Khandelwal Acquisition, Amicus Settlement, China JV Move Add Up?
What is the strategic intent behind Aurobindo’s moves to settle a Galafold patent dispute with Amicus Therapeutics, acquire the non-oncology business of compatriot Khandelwal Labs and get full control of a Chinese JV with Shandong Luoxin?
Scrip - January 9, 2026
What is the strategic intent behind Aurobindo’s moves to settle a Galafold patent dispute with Amicus Therapeutics, acquire the non-oncology business of compatriot Khandelwal Labs and get full control of a Chinese JV with Shandong Luoxin?
Scrip - January 9, 2026
Roche Doubles Down On SCLC By In-Licensing MediLink’s ADC
Deal Snapshot: Roche has scooped up a B7H3 ADC from China’s MediLink just a few months after Daiichi Sankyo temporarily halted enrolling patients in a pivotal Phase III trial with its same-class rival, Merck-partnered ifinatamab deruxtecan (I-DXd).
Scrip - January 9, 2026
Deal Snapshot: Roche has scooped up a B7H3 ADC from China’s MediLink just a few months after Daiichi Sankyo temporarily halted enrolling patients in a pivotal Phase III trial with its same-class rival, Merck-partnered ifinatamab deruxtecan (I-DXd).
Scrip - January 9, 2026
Hisamitsu To Go Private For Long-Term Growth Through $2.6bn MBO
Hisamitsu's CEO is taking the Japanese firm private through a management buyout aimed at securing future growth.
Scrip - January 9, 2026
Hisamitsu's CEO is taking the Japanese firm private through a management buyout aimed at securing future growth.
Scrip - January 9, 2026
Inno Medicine Moves Novel Liposome Into Pivotal Trial For Coronary Plaque
The CEO of Inno Medicine tells Scrip the Chinese company has developed a novel active-targeting nano-liposomal formulation to reverse coronary atherosclerosis plaque, which has yielded positive proof-of-concept Phase Ib/IIa results.
Scrip - January 9, 2026
The CEO of Inno Medicine tells Scrip the Chinese company has developed a novel active-targeting nano-liposomal formulation to reverse coronary atherosclerosis plaque, which has yielded positive proof-of-concept Phase Ib/IIa results.
Scrip - January 9, 2026
Medtech 2026: As Critical New Documents Drop, EU Leaders Look Ahead
The EU's medtech regulatory landscape is shifting, influenced by the Commission's proposed changes. Experts note opportunities and concerns emerging from these reforms, highlighting the need for transparency, efficiency, and adaptability to new technologies by 2026.
Medtech Insight - January 9, 2026
The EU's medtech regulatory landscape is shifting, influenced by the Commission's proposed changes. Experts note opportunities and concerns emerging from these reforms, highlighting the need for transparency, efficiency, and adaptability to new technologies by 2026.
Medtech Insight - January 9, 2026
Global Medtech Guidance Tracker: December 2025
Stay current on regulatory guidelines from around the world with Medtech Insight’s Guidance Tracker. Over 70 documents have been posted on the tracker since its last update.
Medtech Insight - January 9, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight’s Guidance Tracker. Over 70 documents have been posted on the tracker since its last update.
Medtech Insight - January 9, 2026
India’s Medtech Momentum Brings 10-12% Market Growth But Concerns About Stalling Progress in 2026
India’s medical devices industry entered 2026 on the back of steady market growth amid industry warnings over policy inconsistency and ongoing import dependence.
Medtech Insight - January 9, 2026
India’s medical devices industry entered 2026 on the back of steady market growth amid industry warnings over policy inconsistency and ongoing import dependence.
Medtech Insight - January 9, 2026
BSI’s Tunbridge: Notified Bodies ‘Set Up To Fail’ Unless EU Legislative Proposal Changes
Proposal Gives Unrealistic Timelines And Reflects Poor Grasp Of Notified Body Realities
Medtech Insight - January 9, 2026
Proposal Gives Unrealistic Timelines And Reflects Poor Grasp Of Notified Body Realities
Medtech Insight - January 9, 2026
US House Bill On Green Packaging Claims Takes Aim At State-Level Regulations
A new bill introduced in the US House of Representatives seeks to curb the patchwork of packaging regulations for consumer products in different states with a federal standard.
HBW Insight - January 9, 2026
A new bill introduced in the US House of Representatives seeks to curb the patchwork of packaging regulations for consumer products in different states with a federal standard.
HBW Insight - January 9, 2026
People On The Move: Appointments at Karo, Haleon, Pharma Deutschland
Round up of latest European people moves: Karo makes additions to corporate team; Haleon names Portugal head; Pharma Deutschland adds experience.
HBW Insight - January 9, 2026
Round up of latest European people moves: Karo makes additions to corporate team; Haleon names Portugal head; Pharma Deutschland adds experience.
HBW Insight - January 9, 2026
CES Beauty Tech Honorees Offer Window Into Future Skin, Hair Innovations
The Consumer Technology Association’s CES show in Las Vegas Jan. 6-9 showcased breakthrough skin and hair care technologies.
HBW Insight - January 9, 2026
The Consumer Technology Association’s CES show in Las Vegas Jan. 6-9 showcased breakthrough skin and hair care technologies.
HBW Insight - January 9, 2026
Biocon Biologics Adds Keytruda, Herceptin, Opdivo Biosimilars To Its Portfolio
Biocon Biologics continues to build on its oncology portfolio with three new biosimilar candidates, as the integration into a wholly owned subsidiary of Biocon Limited comes closer.
Generics Bulletin - January 9, 2026
Biocon Biologics continues to build on its oncology portfolio with three new biosimilar candidates, as the integration into a wholly owned subsidiary of Biocon Limited comes closer.
Generics Bulletin - January 9, 2026
Hyloris Taps Rosemont To Commercialize Titratable Atomoxetine Oral Solution In US
Latest agreement with Rosemont underscores Hyloris’ value-added medicines strategy and asset-light US partnering.
Generics Bulletin - January 9, 2026
Latest agreement with Rosemont underscores Hyloris’ value-added medicines strategy and asset-light US partnering.
Generics Bulletin - January 9, 2026
Cosette And Alembic Are Among Latest To Benefit From CGT Pathway
Cosette Pharmaceuticals and Alembic Pharmaceuticals are among the latest firms to have benefited from 180 days of competitive generic therapy exclusivity under the US FDA’s CGT pathway. Since the first approval in 2018, almost 500 ANDAs referencing CGT products have been approved.
Generics Bulletin - January 9, 2026
Cosette Pharmaceuticals and Alembic Pharmaceuticals are among the latest firms to have benefited from 180 days of competitive generic therapy exclusivity under the US FDA’s CGT pathway. Since the first approval in 2018, almost 500 ANDAs referencing CGT products have been approved.
Generics Bulletin - January 9, 2026
Alexion Explores Complement Cascade To Defend C5 Leadership
Alexion is leveraging long standing C5 leadership to expand into proximal complement targets and alternative pathway drugs, pairing longer acting and subcutaneous options with genetically guided precision medicines.
In Vivo - January 8, 2026
Alexion is leveraging long standing C5 leadership to expand into proximal complement targets and alternative pathway drugs, pairing longer acting and subcutaneous options with genetically guided precision medicines.
In Vivo - January 8, 2026